Navigation Links
NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director
Date:4/8/2008

HUBBARD, Ohio, April 8, 2008 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC Pink Sheets: NNLX) a nano-biotechnology company announces publication of 2007 financial data and a director appointment.

NanoLogix has posted 2007 unaudited financials. 2007 expenditures were reduced by 42% over 2006, while funding for 2007 Research and Development was increased by 19%. The information can be accessed at: http://www.nanologixinc.com/financials.html

NanoLogix welcomes Bert Pharis to the Board of Directors. Mr. Pharis was formerly President and CEO of Sygnet Wireless, a Cellular Telephone Company in Northeastern Ohio and Western Pennsylvania, from the mid-Eighties until Sygnet's 1998 sale to Dobson Communications. Mr. Pharis then served as a Director of Dobson Communications, sitting on both the Audit and Compensation Committees, through the 2007 sale of Dobson to AT&T. He was President and CEO of Logix Communications, a Competitive Local Exchange Carrier operating primarily in Texas and Oklahoma, from 1999 through 2001. Following that he spent two years as President and CEO of Ortheon Medical, a Medical Device Company in Orlando, Florida.

Bret Barnhizer, CEO of NanoLogix stated, "Bert Pharis is a welcome addition to our new Board of Directors, bringing extensive corporate business expertise in addition to experience with the processes involved in obtaining FDA approval for medical devices."

About NanoLogix, Inc.

NanoLogix is a leading innovator in the research, development, and commercialization of nano-biotechnologies, applications and processes. The Company has 31 granted Patents and multiple Patents Pending for bioreactor- based Hydrogen Production, revolutionary rapid medical testing technologies, and bioremediation. Information on NanoLogix is available at http://www.nanologixinc.com .

This press
'/>"/>

SOURCE NanoLogix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
2. National Public Radio (NPR) Features Broadcast Articles on NanoLogix Hydrogen Bioreactor Operation at Welchs Foods
3. NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program
4. NanoLogix, Inc. Makes Stock Pick List
5. NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update
6. NanoLogix Inc. to Present at EBW Expo & Conference 2007
7. NanoLogix Inc. Announces Historical First in Energy Generation With Bioreactor-Produced Hydrogen at Welchs
8. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
9. Olympus FluoroPoint(TM) System Provides High-Sensitivity Single Molecule and Protein Interaction Analysis for Screening and Research
10. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
11. SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... research executives, scientists, policy makers, and funders today convened ... at the inaugural Partnering for Cures meeting. ... the Milken Institute, convened Partnering for Cures ... discovery into an accessible therapy. This effort unites ...
(Date:12/2/2009)... , - "Bolstering Biodiversity ... Coinciding with the International Year ... hosting an international conference in Libreville,(Gabon) on the ... will be attended by government and state leaders, ...
(Date:12/2/2009)... today announced data presentations on its novel oral JAK2 ... Annual Meeting and Exposition in New Orleans. ,, Data ... Phase 1 dose-escalation trial of SB1518 detailing its safety, ... from 100 to 600 mg. These doses were administered ...
(Date:12/2/2009)... is going through,extraordinary times; markets are in turmoil and ... out that the pharma industry has been,relatively immune to ... During the midst of the ... inaugurated an R&D center in Shanghai, the largest of,its ...
Breaking Biology Technology:Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
... QUEBEC CITY, Nov. 3 /PRNewswire-FirstCall/ - AEterna Zentaris ... biopharmaceutical company focused on,endocrine therapy and oncology, today ... patient recruitment for its Phase 2 trial in ... linked to doxorubicin. The decision to enter the ...
... Halozyme Therapeutics, Inc.,(Nasdaq: HALO ), ... the extracellular matrix, today announced it has ... human hyaluronidase enzyme,(rHuPH20) co-formulations with Humulin(R) R ... lispro) in Type 1 diabetic,patients. This study ...
... Deploys Clustered Storage to Help Redefine the ... Economics of Large-Scale Sequencing, SEATTLE, ... storage, today announced that Complete,Genomics, the world,s first provider of ... of Isilon IQ clustered,storage to unify its vast stores of ...
Other Biology Technology:AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 2Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 3Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 4Complete Genomics Chooses Isilon IQ to Power World's First Complete Human Genome Sequencing Service 2Complete Genomics Chooses Isilon IQ to Power World's First Complete Human Genome Sequencing Service 3
(Date:12/3/2009)... of this message: , , Preliminary Press ... California Academy of Sciences museum, Attention PIOs: Sending ... registration deadline 10 December, News Media registration ... THIS MONDAY, 7 December, Who,s coming, , ...
(Date:12/3/2009)... Rapids, Mich. (Dec. 3, 2009) Van Andel ... hormone abscisic acid (ABA) works at the molecular level to ... cold. Their findings, published in the journal Nature ... around the world and combat global food shortages. The ...
(Date:12/3/2009)... of the upcoming forest deal at Copenhagen in order to ... University of Leeds. , Writing today in Nature ... the carbon credit payments to be agreed at Copenhagen, known ... made to forest dwellers directly, and their property rights assured. ...
Breaking Biology News(10 mins):AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL 28R 29 25 MG and 50 MG 53550 1Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL 28R 29 25 MG and 50 MG 53550 2Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 1Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 2Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 3Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 4Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 5Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 6Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 7Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 8Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 9Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 10Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 11Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 12Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 13Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 14Innophos Holdings Inc Reports Second Quarter 2009 Results 53546 15ProAssurance Reports Second Quarter 2009 Results 53542 1ProAssurance Reports Second Quarter 2009 Results 53542 2ProAssurance Reports Second Quarter 2009 Results 53542 3ProAssurance Reports Second Quarter 2009 Results 53542 4ProAssurance Reports Second Quarter 2009 Results 53542 5ProAssurance Reports Second Quarter 2009 Results 53542 6ProAssurance Reports Second Quarter 2009 Results 53542 7ProAssurance Reports Second Quarter 2009 Results 53542 8ProAssurance Reports Second Quarter 2009 Results 53542 9ProAssurance Reports Second Quarter 2009 Results 53542 10ProAssurance Reports Second Quarter 2009 Results 53542 11ProAssurance Reports Second Quarter 2009 Results 53542 12ProAssurance Reports Second Quarter 2009 Results 53542 13
... by the University of Colorado at Boulder reveals that ... source of fine, organic particle pollutants that contribute to ... Angeles region. , According to the study, a much ... is directly emitted by vehicles and industrial processes. Instead, ...
... 24, 2008) Self-guided treatment for depression could ... , Scientists with the National Space Biomedical Research ... that will assist astronauts in recognizing and effectively ... pose a substantial threat to crew safety and ...
... release is available in German . , ... and molluscs more than plants. This is the finding of ... Research (UFZ), TU Berlin, the German Federal Institute of Hydrology ... of observations before and after the Elbe floods of August ...
Other Biology News:CU-Boulder study suggests air quality regulations miss key pollutants 2Coming soon: Self-guided, computer-based depression treatment 2Coming soon: Self-guided, computer-based depression treatment 3Vegetation hardly affected by extreme flood events 2
... Instech Solomon's laboratory animal infusion kits reduce ... an infusion study while providing sterile equipment ... kit includes everything you need for one ... Tubing and tethers will be cut to ...
The novel and unique HCTplus delivers unmatched information-rich data-dependent LC/MSn data for todays challenge in proteomics and metabonomics work....
... an exciting new chapter to ... leadership, Agilents 7890A GC gives ... take your lab to the ... GC/MS performance, including advanced separation ...
... six short years since publication of the ... widely acclaimed Protein Protocols Handbook, there have ... biochemistry. In recognition of the level of ... evolution of new methodologies directed to study ...
Biology Products: